On July 25, 2025, IceCure Medical Ltd. announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference, where updated positive clinical data for ProSense® cryoablation were presented. Professor Eisuke Fukuma, a leading breast surgeon, presented 17 years of data from over 600 breast cancer patients, demonstrating an impressive 99% recurrence-free rate with cryoablation.
Further solidifying its clinical efficacy, an independent study led by Professor Hisanori Kawamoto, published in the journal Breast Cancer, reported zero (0%) breast cancer local recurrence five years following treatment with ProSense®. This study was honored with the 'Best of Breast Cancer Award' at the conference. These results highlight the potential of ProSense® to significantly improve breast cancer outcomes in Japan.
IceCure's CEO, Eyal Shamir, emphasized the potential impact of ProSense® in Japan, especially given the strong data from independent Japanese studies. The company anticipates strong commercial adoption upon regulatory approval, with its partner Terumo Corporation expected to submit an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for regulatory clearance for breast cancer indication by the end of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.